|
|
||||||||
1Center for Liver, Digestive, and Metabolic Diseases, Laboratory of Pediatrics, University Medical Center Groningen, Groningen; 2TNO Prevention and Health and Departments of General Internal Medicine and Cardiology and of 3Endocrinology and Diabetes, Leiden University Medical Center, Leiden, The Netherlands and the 4Atherosclerosis Department, GlaxoSmithKline Pharmaceuticals, Stevenage, United Kingdom
Submitted 14 April 2005 ; accepted in final form 27 May 2005
Liver X receptor (LXR) agonists have been proposed to act as anti-diabetic drugs. However, pharmacological LXR activation leads to severe hepatic steatosis, a condition usually associated with insulin resistance and type 2 diabetes mellitus. To address this apparent contradiction, lean and ob/ob mice were treated with the LXR agonist GW-3965 for 10 days. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp studies. Hepatic glucose production (HGP) and metabolic clearance rate (MCR) of glucose were determined with stable isotope techniques. Blood glucose and hepatic and whole body insulin sensitivity remained unaffected upon treatment in lean mice, despite increased hepatic triglyceride contents (61.7 ± 7.2 vs. 12.1 ± 2.0 nmol/mg liver, P < 0.05). In ob/ob mice, LXR activation resulted in lower blood glucose levels and significantly improved whole body insulin sensitivity. GW-3965 treatment did not affect HGP under normo- and hyperinsulinemic conditions, despite increased hepatic triglyceride contents (221 ± 13 vs. 176 ± 19 nmol/mg liver, P < 0.05). Clamped MCR increased upon GW-3965 treatment (18.2 ± 1.0 vs. 14.3 ± 1.4 ml·kg1·min1, P = 0.05). LXR activation increased white adipose tissue mRNA levels of Glut4, Acc1 and Fasin ob/ob mice only. In conclusion, LXR-induced blood glucose lowering in ob/ob mice was attributable to increased peripheral glucose uptake and metabolism, physiologically reflected in a slightly improved insulin sensitivity. Remarkably, steatosis associated with LXR activation did not affect hepatic insulin sensitivity.
hepatic glucose production; hepatic steatosis; hyperinsulinemic euglycemic clamp; stable isotopes; triglycerides
This article has been cited by other articles:
![]() |
C. J Delvecchio and J. P Capone Protein kinase C {alpha} modulates liver X receptor {alpha} transactivation J. Endocrinol., April 1, 2008; 197(1): 121 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Talukdar, S. Bhatnagar, S. Dridi, and F. B. Hillgartner Chenodeoxycholic acid suppresses the activation of acetyl-coenzyme A carboxylase-{alpha} gene transcription by the liver X receptor agonist T0-901317 J. Lipid Res., December 1, 2007; 48(12): 2647 - 2663. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nilsson, K. Dahlman-Wright, C. Karelmo, J.-A. Gustafsson, and K. R. Steffensen Elk1 and SRF transcription factors convey basal transcription and mediate glucose response via their binding sites in the human LXRB gene promoter Nucleic Acids Res., July 10, 2007; (2007) gkm492v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Aerts, R. Ottenhoff, A. S. Powlson, A. Grefhorst, M. van Eijk, P. F. Dubbelhuis, J. Aten, F. Kuipers, M. J. Serlie, T. Wennekes, et al. Pharmacological Inhibition of Glucosylceramide Synthase Enhances Insulin Sensitivity Diabetes, May 1, 2007; 56(5): 1341 - 1349. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. M. den Boer, P. J. Voshol, F. Kuipers, J. A. Romijn, and L. M. Havekes Hepatic glucose production is more sensitive to insulin-mediated inhibition than hepatic VLDL-triglyceride production Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1360 - E1364. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Talukdar and F. B. Hillgartner The mechanism mediating the activation of acetyl-coenzyme A carboxylase-{alpha} gene transcription by the liver X receptor agonist T0-901317 J. Lipid Res., November 1, 2006; 47(11): 2451 - 2461. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Lalloyer, B. Vandewalle, F. Percevault, G. Torpier, J. Kerr-Conte, M. Oosterveer, R. Paumelle, J.-C. Fruchart, F. Kuipers, F. Pattou, et al. Peroxisome Proliferator-Activated Receptor {alpha} Improves Pancreatic Adaptation to Insulin Resistance in Obese Mice and Reduces Lipotoxicity in Human Islets Diabetes, June 1, 2006; 55(6): 1605 - 1613. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |